Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease (Q35135672)

6 August 2017

Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease (English)

1 reference

6 August 2017

0 references

4

John C Morris

1 reference

6 August 2017

Chengjie Xiong

1

1 reference

PubMed ID

21335587

6 August 2017

Gerald van Belle

series ordinal

2

1 reference

PubMed ID

21335587

6 August 2017

J Philip Miller

series ordinal

3

1 reference

6 August 2017

1 February 2011

1 reference

6 August 2017

1 reference

6 August 2017

8

1 reference

6 August 2017

1

1 reference

6 August 2017

15-26

1 reference

Power Calculations for General Linear Multivariate Models Including Repeated Measures Applications

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Sample size determination for constrained longitudinal data analysis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Disease-modifying therapies in Alzheimer's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency?

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Disease-modifying therapies for Alzheimer disease: challenges to early intervention

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Power analyses for longitudinal study designs with missing data

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Standardized mean differences in individually-randomized and cluster-randomized trials, with applications to meta-analysis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Strategies for disease modification in Alzheimer's disease

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Sample size estimation for GEE method for comparing slopes in repeated measurements data

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Clinical trial designs for demonstrating disease-course-altering effects in dementia.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Sample size calculations based on slopes and other summary statistics

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Slowing the progression of Alzheimer disease: methodologic issues.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Random-effects models for longitudinal data

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

A new rating scale for Alzheimer's disease.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Optimizing phase II of drug development for disease-modifying compounds.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Alzheimer disease: disease modifying trials; where are we? Where do we need to go? A reflective paper.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Optimal number of repeated measures and group sizes in clinical trials with linearly divergent treatment effects

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Sample-size calculations for studies with correlated ordinal outcomes

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Designing a large prevention trial: statistical issues.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3146242

Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials"

27 September 2018

1 reference

12 December 2020

Guidelines for the design of clinical trials with longitudinal outcomes

1 reference

12 December 2020

Disease modifying trials in Alzheimer disease: methodological and statistical issues

1 reference

12 December 2020

Crossing controls to treatment in repeated-measures trials

1 reference

12 December 2020

Identifiers

DOI

10.1177/1740774510392391

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

PubMed ID

21335587